Bayer Announces Positive Data for Investigational PET Radiotracer

Why It Matters

The results could deliver the first reliable, non‑invasive imaging test for cardiac amyloidosis, accelerating diagnosis and treatment decisions. Successful approval would strengthen Bayer’s radiology portfolio and address a major unmet need in cardiovascular care.

Key Takeaways

• Bayer's I‑124 evuzamitide met Phase III sensitivity and specificity endpoints.
• Study enrolled 170 suspected cardiac amyloidosis patients across 19 U.S. sites.
• Radiotracer holds Breakthrough Therapy and Orphan Drug designations in US/EU.
• Positive data positions Bayer to seek FDA approval for a non‑invasive diagnostic.

Pulse Analysis

Cardiac amyloidosis, a progressive infiltrative disease caused by misfolded protein deposits, remains one of the most under‑diagnosed forms of heart failure. Current diagnostic pathways rely on a combination of invasive biopsies, echocardiography, and nuclear scintigraphy, often leading to delayed treatment and poorer outcomes. With an estimated 400,000 patients worldwide, the market for a definitive, non‑invasive test is sizable, and clinicians are eager for tools that can differentiate between light‑chain (AL) and transthyretin (ATTR) subtypes. Early detection not only improves survival but also reduces costly hospitalizations, making a reliable imaging agent a strategic priority for both payers and pharmaceutical developers.

The investigational tracer I‑124 evuzamitide, originally developed by Attralus and now part of Bayer’s radiology pipeline, targets amyloid deposits with a PET‑compatible isotope. In the REVEAL Phase III study, 170 participants with suspected cardiac amyloidosis received a single intravenous dose followed by PET/CT imaging 3‑5 hours later. Independent readers correctly identified tracer uptake, yielding sensitivity and specificity rates that met the trial’s primary endpoints against a standard‑of‑care reference. The compound’s prior Breakthrough Therapy designation from the FDA and orphan status in both the U.S. and EU underscore its potential to fill a regulatory and clinical gap.

Bayer’s positive topline data positions the company to file a New Drug Application with the FDA later this year, potentially securing the first FDA‑approved PET tracer for cardiac amyloidosis. Approval would not only expand Bayer’s diagnostic portfolio but also create a new revenue stream in a niche yet growing market. For the broader industry, the success of I‑124 evuzamitide could stimulate further investment in molecular imaging agents targeting protein‑misfolding diseases. Patients stand to benefit from faster, more accurate diagnoses, enabling timely initiation of disease‑modifying therapies and ultimately reducing the economic burden of advanced heart failure.